ADAPT HER2+/HR+

Week 1: Prognostic estimation
Week 2-3: Induction therapy (three weeks)
Week 4-12: Efficacy estimation

- T-DM1 mono vs. T-DM1 + endocrine therapy vs. Trastuzumab + endocrine therapy
- Trastuzumab: Loading 8 mg/kg, Preservation 6 mg/kg

Endpoint: pCR vs. pCR vs. pCR

Surgery: EOT

Endocrine therapy